期刊
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
卷 18, 期 12, 页码 3143-3195出版社
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1055-9965.EPI-09-0654
关键词
-
资金
- National Cancer Institute [N01-PC-64402]
Potential reduced exposure products (PREPS) to tobacco toxicants may have promise in reducing tobacco-related morbidity or mortality or may promote greater harm to individuals or the population. Critical to determining the risks or benefits from these products are valid human clinical trial PREP assessment methods. Such an assessment involves determining the effects of these products on biomarkers of exposure and effect, which serve as proxies for harm, and assessing the potential for consumer uptake and abuse of the product. This article identifies critical methodologic issues associated with PREP assessments, reviews the methods that have been used to assess PREPS, and describes the strengths and limitations of these methods. Additionally, recommendations are provided for clinical trial PREP assessment methods and future research directions in this area based on this review and on the deliberations from a National Cancer Institute sponsored Clinical Trials PREP Methods Workshop. (Cancer Epidemiol Biomarkers Prev 2009;18(12):3143-95)
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据